Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

– $28.6 million of Revuforj^® (revumenib) net revenue, representing 43% growth over 1Q25 –

– $36.2 million of Niktimvo™ (axatilimab-csfr) net revenue reported by Incyte in first full quarter of launch; $9.4 million in collaboration revenue reported by Syndax –

Read more at globenewswire.com